FluorouracilRecent, repeatedEvidence- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Fluorouracil” · registered Sep 2026
- NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “5Fluorouracil” · registered Feb 2026
- NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “5-Fluorouracil” · registered Jan 2026
- NCT06628310 · AbbVie · Phase 2 · live · background · “Fluorouracil” · registered Oct 2024
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “5-FU” · registered Jul 2023
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 67 studies | 77 studies | background 11 · comparator 1 |
OxaliplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Oxaliplatin” · registered Sep 2026
- NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Oxaliplatin” · registered Feb 2026
- NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “Oxaliplatin” · registered Jan 2026
- NCT06628310 · AbbVie · Phase 2 · live · background · “Oxaliplatin” · registered Oct 2024
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Oxaliplatin” · registered Jul 2023
| Sanofi35% of its industry studies | 67 studies | 77 studies | background 10 · comparator 1 |
LeucovorinRecent, repeatedEvidence- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Leucovorin Calcium” · registered Sep 2026
- NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Leucovorin” · registered Feb 2026
- NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “Leucovorin” · registered Jan 2026
- NCT06628310 · AbbVie · Phase 2 · live · background · “Leucovorin” · registered Oct 2024
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Leucovorin” · registered Jul 2023
| Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed | 67 studies | 66 studies | background 9 · comparator 1 |
NivolumabRecent, repeatedEvidence- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Nivolumab” · registered Sep 2026
- NCT07546812 · Gilead Sciences · Phase 2 · live · background · “Nivolumab” · registered Apr 2026
- NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Nivolumab” · registered Feb 2026
- NCT07392892 · Pfizer · Phase 3 · live · comparator · “Nivolumab” · registered Jan 2026
- NCT07431281 · AstraZeneca · Phase 3 · live · background · “Nivolumab” · registered Jan 2026
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 66 studies | 55 studies | background 4 · comparator 2 |
CapecitabineRecent, repeatedEvidence- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Capecitabine” · registered Sep 2026
- NCT07432295 · I-Mab Biopharma US Limited · Phase 2 · live · background · “Capecitabine” · registered Feb 2026
- NCT07431281 · AstraZeneca · Phase 3 · live · background · “Capecitabine” · registered Jan 2026
- NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “Capecitabine” · registered Mar 2024
- NCT05568095 · Arcus Biosciences, Inc. · Phase 3 · background · “Capecitabine” · registered Oct 2022
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 55 studies | 66 studies | background 9 |
PaclitaxelRecent, repeatedEvidence- NCT07546812 · Gilead Sciences · Phase 2 · live · background · “Paclitaxel” · registered Apr 2026
- NCT06356311 · Merck & Co., Inc · Phase 3 · live · comparator · “Paclitaxel” · registered Apr 2024
- NCT04499924 · Pfizer · Phase 3 · background · “paclitaxel” · registered Jul 2020
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 22 studies | 22 studies | background 2 · comparator 1 |
LevoleucovorinRecent, repeatedEvidence- NCT07818070 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · background · “Levoleucovorin” · registered Sep 2026
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Levoleucovorin” · registered Jul 2023
- NCT04210115 · Merck & Co., Inc · Phase 3 · background · “levoleucovorin” · registered Dec 2019
| Aurobindo Pharma100% of its industry studies | 22 studies | 22 studies | background 3 |
DocetaxelRecent, repeatedEvidence- NCT06356311 · Merck & Co., Inc · Phase 3 · live · comparator · “Docetaxel” · registered Apr 2024
- NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “Docetaxel” · registered Mar 2024
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 22 studies | 22 studies | background 1 · comparator 1 |
IrinotecanRecent, repeatedEvidence- NCT06356311 · Merck & Co., Inc · Phase 3 · live · comparator · “Irinotecan” · registered Apr 2024
- NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Irinotecan” · registered Jul 2023
| Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016) | 22 studies | 22 studies | comparator 1 · background 1 |